BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 23656337)

  • 21. Phentermine and topiramate extended-release for the obesity: new kids on the block.
    Katsi V; Marketou M; Kallistratos MS; Tousoulis D; Makris T; Manolis AJ; Vardas P; Kallikazaros I
    Recent Pat Cardiovasc Drug Discov; 2013 Apr; 8(1):35-41. PubMed ID: 23565717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two anti-obesity hopefuls and their safety.
    Bello NT; Campbell SC
    Expert Opin Drug Saf; 2012 Sep; 11(5):681-3. PubMed ID: 22788876
    [No Abstract]   [Full Text] [Related]  

  • 23. Phentermine plus topiramate in the treatment of obesity.
    Malgarini RB; Pimpinella G
    Lancet; 2011 Jul; 378(9786):125-6; author reply 126-7. PubMed ID: 21742167
    [No Abstract]   [Full Text] [Related]  

  • 24. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
    Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
    J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phentermine and topiramate for the management of obesity: a review.
    Cosentino G; Conrad AO; Uwaifo GI
    Drug Des Devel Ther; 2013; 7():267-78. PubMed ID: 23630412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phentermine/topiramate for the treatment of obesity.
    Smith SM; Meyer M; Trinkley KE
    Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy comparison of medications approved for chronic weight management.
    Kumar RB; Aronne LJ
    Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.
    Dalai SS; Adler S; Najarian T; Safer DL
    Contemp Clin Trials; 2018 Jan; 64():173-178. PubMed ID: 29038069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2 new drugs for weight loss.
    Med Lett Drugs Ther; 2012 Sep; 54(1398):69-71. PubMed ID: 22992487
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
    Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
    JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity Pharmacotherapy.
    Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
    Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New medications for weight loss.
    Murfin M
    JAAPA; 2012 Dec; 25(12):59-60. PubMed ID: 23600006
    [No Abstract]   [Full Text] [Related]  

  • 34. Phentermine and topiramate extended release (Qsymia™): first global approval.
    Cameron F; Whiteside G; McKeage K
    Drugs; 2012 Oct; 72(15):2033-42. PubMed ID: 23039320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
    Gadde KM; Pritham Raj Y
    Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
    Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
    Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
    Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
    Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Panel meeting prompts excitement for antiobesity drug.
    Mullard A
    Lancet; 2012 Mar; 379(9819):882. PubMed ID: 22413140
    [No Abstract]   [Full Text] [Related]  

  • 39. The FDA's assessment of two drugs for chronic weight management.
    Colman E; Golden J; Roberts M; Egan A; Weaver J; Rosebraugh C
    N Engl J Med; 2012 Oct; 367(17):1577-9. PubMed ID: 23050510
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacological therapies for obesity.
    Kaplan LM
    Gastroenterol Clin North Am; 2005 Mar; 34(1):91-104. PubMed ID: 15823441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.